Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists
A method is disclosed utilizing a cannabinoid receptor type 2-receptor-selective agonist for treating or preventing lower urinary tract dysfunction, including overactive bladder, lower urinary tract symptoms and detrusor overactivity.
1 . A method for treating or preventing lower urinary tract dysfunction in a mammal, which comprises administering to said mammal a therapeutically effective amount of a CB2-receptor-selective agonist.
2 . The method of claim 1 , wherein said CB2-receptor-selective agonist is peripherally selective.
3 . The method of claim 2 , wherein said CB2-receptor-selective agonist is a compound of Formula I:
or a pharmaceutically acceptable salt, ester or solvate thereof.
4 . The method of claim 1 , wherein said CB2-receptor-selective agonist is a compound of Formula II:
or a pharmaceutically acceptable salt, ester or solvate thereof.
5 . The method of claim 1 , wherein said CB2-receptor-selective agonist is a compound of Formula III:
or a pharmaceutically acceptable salt, ester or solvate thereof.
6 . The method of claim 1 , wherein said CB2-receptor-selective agonist is a compound of Formula IV:
or a pharmaceutically acceptable salt, ester or solvate thereof.
7 . A method for treating or preventing overactive bladder, lower urinary tract symptoms or detrusor overactivity in a mammal, which comprises administering to said mammal a therapeutically effective amount of a CB2-receptor-selective agonist.
8 . A method for preserving an ability to empty the bladder in a mammal, which comprises administering to said mammal a therapeutically effective amount of a CB2-receptor-selective agonist.
9 . A method for preventing deterioration of or protecting bladder contractility in a mammal, which comprises administering to said mammal a therapeutically effective amount of a CB2-receptor-selective agonist.
10 . A method for improving bladder function in a mammal, which comprises administering to said mammal a compound of Formula I below:
or a pharmaceutically acceptable salt, ester or solvate thereof.
11 . The method of claim 3 , wherein said CB2-receptor-selective agonist is administered orally in a total daily dose of about 10 mg to about 300 mg.